LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Amphastar Pharmaceuticals Inc

Closed

SectorHealthcare

19.32 -5.25

Overview

Share price change

24h

Current

Min

18.87

Max

20.28

Key metrics

By Trading Economics

Income

-14M

17M

Sales

-8.7M

183M

P/E

Sector Avg

9.297

66.845

EPS

0.93

Profit margin

9.044

Employees

2,028

EBITDA

-3.4M

39M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+52.64% upside

Dividends

By Dow Jones

Next Earnings

6 May 2026

Market Stats

By TradingEconomics

Market Cap

-304M

977M

Previous open

24.57

Previous close

19.32

News Sentiment

By Acuity

54%

46%

279 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Mar 2026, 19:32 UTC

Acquisitions, Mergers, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

6 Mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 Mar 2026, 22:26 UTC

Major News Events

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 Mar 2026, 22:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 Mar 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 Mar 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 Mar 2026, 21:50 UTC

Market Talk
Major News Events

Financial Services Roundup: Market Talk

6 Mar 2026, 21:37 UTC

Earnings

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 Mar 2026, 21:25 UTC

Major News Events

How The Iran War Impacts Ukraine. -- Barrons.com

6 Mar 2026, 21:17 UTC

Earnings

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 Mar 2026, 20:50 UTC

Earnings

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 Mar 2026, 20:46 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 Mar 2026, 20:31 UTC

Major News Events

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 Mar 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 Mar 2026, 20:12 UTC

Market Talk
Major News Events

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 Mar 2026, 19:10 UTC

Market Talk
Major News Events

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 Mar 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 Mar 2026, 18:44 UTC

Market Talk
Major News Events

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 Mar 2026, 18:08 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 Mar 2026, 18:04 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 Mar 2026, 18:04 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 Mar 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 Mar 2026, 17:46 UTC

Major News Events

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 Mar 2026, 17:40 UTC

Market Talk
Earnings

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 Mar 2026, 17:40 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 Mar 2026, 17:32 UTC

Market Talk
Major News Events

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 Mar 2026, 17:28 UTC

Market Talk
Major News Events

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 Mar 2026, 17:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

6 Mar 2026, 17:20 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

6 Mar 2026, 17:20 UTC

Acquisitions, Mergers, Takeovers

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Comparison

Price change

Amphastar Pharmaceuticals Inc Forecast

Price Target

By TipRanks

52.64% upside

12 Months Forecast

Average 31.2 USD  52.64%

High 38 USD

Low 28 USD

Based on 5 Wall Street analysts offering 12 month price targets forAmphastar Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

23.91 / 25.04Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

279 / 351 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat